Tyrosine kinase inhibitor imatinib (STI571) as an anticancer agent for solid tumours

Annals of Medicine

Volumn 33, Issue 7, 2001, Pages 451-455

  Joensuu, H ^a   Dimitrijevic, S ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

c kit; Chronic myeloid leukaemia; Gastrointestinal stromal tumour; Imatinib; Platelet derived growth factor receptor; Positron emission tomography; Sarcoma; Signal transduction; STI571

Indexed keywords

BCR ABL PROTEIN; GLEEVE; IMATINIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANEMIA; AUTOPHOSPHORYLATION; BLEEDING; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG RESPONSE; EDEMA; FACE EDEMA; GASTROINTESTINAL TUMOR; GENE OVEREXPRESSION; HUMAN; MUSCLE CRAMP; MYALGIA; NAUSEA; NEUTROPENIA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RASH; REVIEW; SOLID TUMOR; THROMBOCYTOPENIA;

EID: 0034785836     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.3109/07853890109002093     Document Type: Review

References (13)

1. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
2. ZD1839 ('Iressa') as an anticancer agent
3. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins
4. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
5. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
6. Gastrointestinal stromal tumors: Their origin and cause
7. Gastrointestinal stromal tumors definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis
8. Two hundred gastrointestinal stromal tumors: Recurrence patterns and prognostic factors for survival
9. Stem cell factor and hematopoiesis
10. Effect of the tyrosine kinase inhibitor STI571 in a patient with metastatic gastro-intestinal stromal tumor
11. Evaluation of the safety and efficacy of an oral molecularly-targeted therapy, STI571, in patients with unresectable or metastatic gastrointestinal stromal tumors (GISTs) expressing C-KIT (CD117)
12. STI571, an active drug in metastatic gastrointestinal stromal tumors (GIST), an EORTC phase I study
13. F18-FDG-PET provides early evidence of biological response to STI571 in patients with malignant gastrointestinal stromal tumors (GIST)